Featured: Preliminary Results for the Year Ended 31 March 2017
Board change
Preliminary Results for the Year Ended 31 March 2017
FDA approves cryopreserved formulation of ReNeuron’s retinal stem cell therapy candidate
Notification of Preliminary Results
ReNeuron progresses clinical and regulatory strategy for the US with stroke programme based on positive FDA regulatory feedback
at 2017-07-21 16:35:00
15 minute delayed share price from London Stock Exchange provided by Euroland.
